Pfizer

PFE · NYSE

$30.11+$0.67 (+2.28%)TodayMarket closed ·
Prev close $29.44

News sentiment

Tone of recent coverage

Social media sentiment, last 30 days

Average tone of posts mentioning PFE, from −1 (all negative) to +1 (all positive). Latest day: +0.00 across 22 mentions.

Latest news

  • NewsVandana Singh

    Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts

  • NewsMohd Haider

    JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms

  • NewsEvette Mitkov

    Pfizer Stock Hits 52-Week High: What's Going On?

  • Press releaseBusiness Wire

    Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

  • NewsAnanya Gairola

    Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

  • NewsNeeraj Jain

    A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

  • NewsMohd Haider

    Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’

  • NewsVandana Singh

    Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease

  • Press releaseBusiness Wire

    Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

  • Press releasePRNewswire

    Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

  • Press releaseBusiness Wire

    Pfizer Declares Fourth-Quarter 2026 Dividend

  • NewsVandana Singh

    Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims

  • NewsVandana Singh

    Vaxcyte Stock Hits New 52-Week High - Here’s Why

  • News

    Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency

  • Press releaseBusiness Wire

    Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

  • NewsVandana Singh

    Pfizer Says Eczema Drug Shows Significant Skin Clearance

  • Press releaseBusiness Wire

    Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

  • News

    10 Health Care Stocks With Whale Alerts In Today’s Session

  • NewsVandana Singh

    Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

  • News

    Full Transcript: Pfizer Q2 2026 Earnings Call

  • Press releaseBusiness Wire

    Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

  • Press releaseBusiness Wire

    Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

  • NewsVandana Singh

    Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer

  • NewsVandana Singh

    Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer

  • Press releaseBusiness Wire

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

  • Press releaseGlobe Newswire

    A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

  • NewsRadhika Anilkumar Nadig

    Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food

  • Press releaseBusiness Wire

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

  • NewsVandana Singh

    Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

  • NewsNamrata Sen

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

  • NewsAvi Kapoor

    Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’

  • News

    QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax

  • NewsAvi Kapoor

    Dow Jumps Over 900 Points As Crude Oil Falls: Investor Sentiment Improves Further, Fear Index Moves To ‘Greed’ Zone

  • NewsVandana Singh

    Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss

  • NewsAvi Kapoor

    Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings

  • NewsEva Mathew

    Stock Market Today: S&P 500, Dow and Nasdaq Futures Gain as Scott Bessent Says Hormuz Deal Could Come Soon— Caterpiller, Palantir in Focus (UPDATED)

  • Press releasePRNewswire

    NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off

  • News

    Pfizer Q2 Adj. EPS $0.77 Beats $0.69 Estimate, Sales $15.034B Beat $14.412B Estimate

  • Press releaseBusiness Wire

    Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

  • Press releaseBusiness Wire

    Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

  • Press releaseBusiness Wire

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

  • Press releaseBusiness Wire

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

  • Press releaseBusiness Wire

    Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

  • NewsAvi Kapoor

    How To Earn $500 A Month From Pfizer Stock Ahead Of Q1 Earnings

  • Press releaseBusiness Wire

    Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.